POMDOCTOR LIMITED Announces Receipt of Nasdaq Staff Delisting Determination
A timely hearing request would keep suspension and the delisting filing on hold pending the Nasdaq panel's decision.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pomdoctor (POM) received a Nasdaq staff delisting determination after its American depositary shares failed the exchange's minimum bid price requirement.
The October 6 letter cited closing bids below $1.00 for 30 consecutive business days, from August 24 through October 5, 2026. A 1-for-18 reverse stock split on June 22, 2026 made the company ineligible for the usual 180-calendar-day compliance period.
Pomdoctor intends to request a hearing by October 13, 2026 and present a compliance plan. A timely request would stay trading suspension and the delisting filing pending the panel's decision. Without a timely appeal, trading will be suspended at the opening of business on October 15, 2026, and Nasdaq will file to remove the securities from listing and registration.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Pomdoctor intends to appeal and present a plan to regain minimum bid price compliance.
- Minor point. Forward-looking: it has not happened yet and may not happen.A timely hearing request would stay suspension and the delisting filing pending the panel's decision.
Negative
- Major pointADS closing bids below $1.00 for 30 consecutive business days triggered Nasdaq's staff delisting determination.
- Major point. Forward-looking: it has not happened yet and may not happen.Absent a timely appeal by October 13, 2026, trading suspension begins October 15, followed by a delisting filing.
- Moderate pointThe June 22, 2026 reverse split makes Pomdoctor ineligible for the usual 180-calendar-day compliance period.
Details
Market move: POM -8.56% vs previous close. Nasdaq delisting determination
On Oct 9, the day this news came out, the latest delayed price for POM is 8.56% below the previous close. Argus tracked a trough of -18.4% from its starting point during tracking. Our momentum scanner has recorded 8 alerts for this stock so far that day. The latest delayed price is $0.70. Relative volume is very high at 3.5x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Minimum bid price threshold
- $1.00 per share
- Nasdaq minimum bid price requirement
- Time below threshold
- 30 consecutive business days
- From August 24 through October 5, 2026
- Reverse stock split
- 1-for-18
- Effected June 22, 2026; cited as the reason the company is ineligible for a compliance period
- Ordinary compliance period
- 180 calendar days
- Ordinarily available to Nasdaq-listed companies, but not available to the company
- Hearing request deadline
- October 13, 2026
- Deadline to appeal the staff determination
- Potential trading suspension
- October 15, 2026
- Would begin at the opening of business unless the company timely appeals
Key Terms
reverse stock split financial
form 25-nse regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
The Letter notified the Company that the closing bid price of the Company's American depositary shares (the "ADSs") had been below
Ordinarily, a Nasdaq-listed company would be afforded a 180-calendar-day period to regain compliance with the Minimum Bid Price Requirement. However, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv), the Company is not eligible for any compliance period because the Company effected a 1-for-18 reverse stock split on June 22, 2026, within the prior one-year period.
Accordingly, the Staff determined that the Company's securities are subject to delisting from The Nasdaq Global Market. Unless the Company timely appeals the Staff's determination to a Nasdaq Hearings Panel (the "Panel"), the Company's securities will be suspended from trading at the opening of business on October 15, 2026, and Nasdaq will file a Form 25-NSE with the
The Company intends to timely request a hearing before the Panel to appeal the Staff's determination and to present a plan to regain compliance with the Minimum Bid Price Requirement. The deadline for the Company to request a hearing is October 13, 2026. A timely hearing request will stay the suspension of the Company's securities and the filing of the Form 25-NSE pending the Panel's decision. Accordingly, no suspension or delisting action will take effect while the appeal remains pending.
The Company is evaluating the alternatives available to it to regain compliance with Nasdaq's continued listing requirements. However, there can be no assurance that the Panel will grant the Company an extension of time to regain compliance, that the Company will regain or maintain compliance with the Minimum Bid Price Requirement or any other Nasdaq continued listing requirement, or that the Company's appeal will be successful.
About POMDOCTOR LIMITED
POMDOCTOR LIMITED (Nasdaq: POM) is a digital healthcare company focused on advancing AI-enabled healthcare solutions and expanding predictive healthcare capabilities. The Company leverages physician resources, wearable technologies, artificial intelligence, healthcare payment networks and real-world healthcare data to support more personalized, continuous and data-driven healthcare services. For more information, please visit the Company's website: http://ir.7shiliu.com.
Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements include, without limitation, statements concerning the Company's intention to request a hearing before the Panel, the anticipated effect of a timely hearing request, the Company's appeal of the Staff's determination, the Company's plan and ability to regain and maintain compliance with Nasdaq's continued listing requirements, the Panel's consideration of the Company's appeal and compliance plan, and the continued listing of the Company's securities on Nasdaq.
Forward-looking statements involve risks and uncertainties, and actual results may differ materially from those expressed or implied by such statements. Factors that could cause actual results to differ materially include, among others, the Panel's determination regarding the Company's appeal, the Company's ability to regain and maintain compliance with the Minimum Bid Price Requirement and other Nasdaq continued listing requirements, fluctuations in the market price of the Company's ADSs, and the other risks and uncertainties described in the Company's filings with the U.S. Securities and Exchange Commission.
The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances occurring after the date of this press release, except as required by applicable law.
Investor Relations Contact
POMDOCTOR LIMITED
Investor Relations Department
Email: ir@7lk.com
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
View original content:https://www.prnewswire.com/news-releases/pomdoctor-limited-announces-receipt-of-nasdaq-staff-delisting-determination-302903228.html
SOURCE POMDOCTOR LIMITED
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Why did Pomdoctor (POM) receive a Nasdaq delisting determination?
Pomdoctor's American depositary shares closed below $1.00 for 30 consecutive business days, from August 24 through October 5, 2026. This breached Nasdaq's minimum bid price requirement. Its June 22, 2026 reverse split occurred within the prior year, making it ineligible for the usual 180-calendar-day compliance period.
When must Pomdoctor (POM) appeal, and would an appeal stop trading suspension?
Pomdoctor must request a hearing by October 13, 2026; a timely request would stay suspension and the delisting filing pending the panel's decision. The company intends to appeal and present a compliance plan. Without a timely appeal, trading will be suspended at the opening of business on October 15, 2026.